The Journal of Pediatrics
Volume 152, Issue 5 , Pages 685-689 , May 2008

Double-blind Placebo-Controlled Trial of Amitriptyline for the Treatment of Irritable Bowel Syndrome in Adolescents

  • Ron J. Bahar, MD

      Affiliations

    • Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, UCLA Geffen School of Medicine, Los Angeles, CA
    • Corresponding Author InformationReprint requests: Ron Bahar, MD, UCLA Geffen School of Medicine, 5363 Balboa Blvd, Suite 540, Encino, CA 91316.
    • ,
  • Brynie S. Collins, MD

      Affiliations

    • Children's Hospital Los Angeles, Keck-USC School of Medicine, Los Angeles, CA.
    • ,
  • Barry Steinmetz, MD

      Affiliations

    • Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, UCLA Geffen School of Medicine, Los Angeles, CA
    • ,
  • Marvin E. Ament, MD

      Affiliations

    • Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, UCLA Geffen School of Medicine, Los Angeles, CA

Received 1 June 2007 ,Revised 27 September 2007 ,Accepted 15 October 2007.

References 

  1. Hyams JS, Burke G, Davis PM, Rzepski B, Andrulonis PA. Abdominal pain and irritable bowel syndrome in adolescents: a community-based study. J Pediatr. 1996;129:220–226
  2. Rasquin-Weber A, Hyman PE, Cucchiara S, Fleisher DR, Hyams JS, Milla PJ, et al. Childhood functional gastrointestinal disorders. Gut. 1999;45(Suppl 2):1160–1168
  3. Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, et al. Childhoold functional gastrointestinal disorders: child/adolescent. Gastroenterology. 2006;130:1527–1537
  4. Kline RM, Kline JJ, Di Palma J, Barbero GJ. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr. 2001;138:125–128
  5. Rajagopalan M, Kurian G, John J. Symptom relief with AMI in the irritable bowel syndrome. J Gastroenterol Hepatol. 1998;13:738–741
  6. Alderton HR. Tricyclic medication in children and the QT interval: case report and discussion. Can J Psychiatr. 1995;40:32–39
  7. Patrick DL, Drossman DA, Ihunnaya OF. A quality of life measure for persons with irritable bowel syndrome (IBS-QOL): user's manual and scoring diskette for United States version. Seattle: University of Washington; 1997;
  8. Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, et al. Design of treatment trials for gastrointestinal disorders. Gastroenterology. 2006;130:1538–1551
  9. Schmulson M, Lee OY, Chang L, Naliboff B, Mayer EA. Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol. 1999;94:2929–2935
  10. Smith GA, Strausbaugh SD, Harbeck-Weber C, Cohen DM, Shields BJ, Powers JD. New non-cocaine-containing topical anesthetics compared with tetracaine-adrenaline-cocaine during repair of lacerations. Pediatrics. 1997;100:825–830
  11. McGrath PA. Pain in children: nature, assessment, & treatment. New York: The Guilford Press; 1990;
  12. Poitras P, Riberdy , Poitras M, Plourde V, Boivin M, Verrier P. Evolution of visceral sensitivity in patients with irritable bowel syndrome. Dig Dis Sci. 2002;47:914–920
  13. Vedantam S. Child antidepressant warning is urged (Panel's recommendation to FDA comes as use of medications has soared) (The Washington Post 2004). 2004;September 15, A2
  14. Harris G. F.D.A. panel urges stronger warning on antidepressants. nytimes.comSeptember 15, 2004
  15. From Food and Drug Administration/Center for Drug Evaluation and Research Official Website. http://www.fda.gov/cder/drug/antidepressants/default.htmupdated February 3, 2005
  16. Centers for Disease Control and Prevention. Health, United States, 2006, with Chartbook on Trends in the Health of Americans. www.cdc.gov http://www.cdc.gov/nchs/data/hus/hus06.pdfreleased February, 2007
  17. Childs D. Some experts blame FDA labeling for child suicide increase (Warnings on antidepressant labels may scare doctors, parents away from necessary treatment). abcnews.go.comFebruary 5, 2007
  18. Gur A, Karakoc M, Nas K, Cevik R, Sarac J, Ataoglu S. Effects of low power laser and low dose amitytriptyline therapy on clinical symptoms and quality of life in fibromyalgia: a single-blind, placebo-controlled trial. Rheumatol Int. 2002;22:188–193
  19. Plesh O, Curtis D, Levine J, McCall WD. Amitriptyline treatment of chronic pain in patients with temporomandibular disorders. J Oral Rehabil. 2000;27:834–841
  20. Cournoyer G, de Montigny C, Ouellette J, Langlois R, Elie R, Caille G, et al. A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade. J Clin Psychopharmacol. 1987;7:385–393
  21. Soloff PH, George A, Nathan S, Schulz PM, Cornelius JR, Herring J, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol. 1989;9:238–246
  22. Tack J, Broekaert D, Fischler B, Oudenhove LV, Gevers Am, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006;55:1095–1103
  23. Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized study. Aliment Pharmacol Ther. 2005;22:381–385
  24. Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastoenterology. 2006;130:1527–1537
  25. Thiwan SIM, Drossman DA. Treatment of functional GI disorders with psychotropic medicines: a review of evidence with a practical approach. Gastroenterol Hepatol. 2006;2:678–688
  26. De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61:317–332
  27. Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine, and citalopram in animal models of acute persistent and neuropathic pain. Neuropharmacology. 2005;48:252–263
  28. Hyams JS. Irritable bowel syndrome, functional dyspepsia, and functional abdominal pain syndrome. Adolesc Med Clin. 2004;14:1–15
  29. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–3506
  30. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557–563

 Supported by James L. Brooks and the Diane Brooks Medical Research Foundation of the California Community Foundation (Los Angeles, CA), as well as by AstraZeneca, LP (Wayne, PA).

PII: S0022-3476(07)00976-6

doi: 10.1016/j.jpeds.2007.10.012

The Journal of Pediatrics
Volume 152, Issue 5 , Pages 685-689 , May 2008

Article Tools

* Image Usage & Resolution